{"entity":{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","aka":["ROWAN"],"tldr":"A phase 2 trial of Durvalumab in hepatocellular carcinoma, run by Boston Scientific Corporation, active and no longer recruiting.","summary":"TheraSphere With Durvalumab and Tremelimumab for HCC is a phase 2 interventional study registered as NCT05063565 by Boston Scientific Corporation, with 100 participants planned, started 2023-11-03 and due to reach its primary completion in 2027-06. Interventions recorded: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05063565","url":"https://clinicaltrials.gov/study/NCT05063565"}],"tags":["ctgov-ingest"],"related":["y-90"],"indications":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab"],"companies":["boston-scientific"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05063565","phase":"2","setting":"An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)","sponsor":"Boston Scientific Corporation","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05063565/","neighbours":{"isotope":[{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}],"indication":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/"}],"pairing":[{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/"}]}}